- Condition: Healthy Volunteers
Interventions: Drug: LY2979165; Drug: LY2140023; Other: Placebo; Other: Ketamine
Sponsor: Eli Lilly and Company
Not yet recruiting - verified January 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Placebo Moxifloxacin; Drug: Moxifloxacin; Drug: GSK573719/Vilanterol 125/25mcg; Drug: GSK573719; Drug: GSK573719/Vilanterol 500/100mcg; Drug: Placebo DPI
Sponsor: GlaxoSmithKline
Recruiting - verified January 2012 - Condition: Cerebral Vasculature
Intervention: Other: cocoa
Sponsors: NHS Greater Glasgow and Clyde; University of Glasgow
Not yet recruiting - verified January 2012 - Condition: HIV
Interventions: Biological: EN41-FPA2 HIV vaccine; Biological: EN41-FPA2 HIV vaccine; Biological: EN41-FPA2 HIV vaccine; Biological: EN41-FPA2 HIV vaccine; Biological: Na Cl Placebo vaccine
Sponsors: PX'Therapeutics; European Commission
Recruiting - verified January 2012 - Condition: Tuberculosis
Interventions: Biological: Aerosol inhaled MVA85A; Biological: Intradermal MVA85A
Sponsor: University of Oxford
Recruiting - verified January 2012 - Condition: Healthy
Interventions: Drug: MLDL1278A; Drug: MLDL1278A
Sponsors: BioInvent International AB; Genentech
Recruiting - verified December 2011 - Condition: Cough
Interventions: Drug: GSK2339345 (solution); Drug: GSK2339345 (nebulised); Drug: Placebo (0.9% sodium chloride solution); Drug: Lidocaine
Sponsor: GlaxoSmithKline
Recruiting - verified December 2011 - Condition: Hepatitis C
Intervention: Drug: Sildenafil and Boceprevir
Sponsor: Imperial College London
Not yet recruiting - verified December 2011 - Condition: Healthy Volunteers
Interventions: Drug: NI-0501; Drug: Placebo
Sponsor: NovImmune SA
Recruiting - verified October 2011 - Condition: RSV Infection
Interventions: Drug: MEDI-557; Other: Placebo
Sponsor: MedImmune LLC
Recruiting - verified January 2012 - Condition: Parkinson's Disease
Interventions: Drug: AZD3241 ER formulation 1; Drug: Placebo; Drug: AZD3241 Alternative titration scheme with formulation 1 or 2
Sponsor: AstraZeneca
Recruiting - verified November 2011 - Condition: Asthma
Interventions: Drug: GSK2269557; Drug: GSK2269557 matching placebo
Sponsor: GlaxoSmithKline
Recruiting - verified October 2011 - Condition: Healthy
Interventions: Drug: Capsule ASA 81mg/esomeprazole 20mg; Drug: Acetylsalicylzuur Apotex Cardio
Sponsor: AstraZeneca
Recruiting - verified November 2011 - Condition: Pain, Neuropathic
Interventions: Drug: Gabapentin lower dose; Drug: Donepezil; Other: Placebo (Dop); Other: Placebo (Gaba); Drug: Gabapentin higher dose
Sponsor: GlaxoSmithKline
Recruiting - verified November 2011 - Condition: Invasive Pneumococcal Disease
Interventions: Biological: 13-valent pneumococcal conjugate vaccine; Biological: 10-valent pneumococcal conjugate vaccine
Sponsor: University of Oxford
Not yet recruiting - verified September 2011 - Condition: Pneumococcal Disease
Interventions: Biological: Prevenar 13; Biological: Pneumovax II
Sponsors: University of Oxford; Mason Medical Research Foundation
Not yet recruiting - verified August 2011 - Condition: Streptococcus Pneumoniae
Intervention:
Sponsor: Dr. Elizabeth Miller
Recruiting - verified August 2011 - Condition: Sepsis
Intervention: Biological: Lipopolysaccharide infusion
Sponsor: University of Nottingham
Recruiting - verified October 2011 - Conditions: Healthy; Diabetes Mellitus, Type 2
Interventions: Drug: oral NNC 0113-0987; Drug: oral NNC 0113-0987; Drug: I.v. NNC 0113-0987; Drug: oral placebo
Sponsor: Novo Nordisk
Recruiting - verified November 2011 - Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Single dose reduced; Drug: Single dose standard; Drug: Multiple Dose; Drug: Multiple Dose
Sponsors: Biogen Idec; Biogen Idec Ltd.
Recruiting - verified December 2011 - Conditions: Typhoid Fever; Enteric Fever; Typhoid
Interventions: Biological: Vaccine placebo (excipients only); Biological: Ty21a; Biological: M10ZH09 vaccine
Sponsors: University of Oxford; Wellcome Trust; Imperial College London; University of Maryland
Recruiting - verified December 2011 - Study to Examine the Effect of Ulimorelin on the Pharmacokinetics of Midazolam in Healthy VolunteersCondition: Digestive System Disorders
Interventions: Drug: Midazolam; Drug: Ulimorelin
Sponsor: Norgine
Recruiting - verified July 2011 - Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid and PlasmaCondition: Healthy
Interventions: Drug: CAZ104; Drug: CAZ104
Sponsor: AstraZeneca
Recruiting - verified October 2011 - Condition: Atopic Dermatitis
Interventions: Drug: LEO 29102; Drug: Placebo
Sponsor: LEO Pharma
Recruiting - verified August 2011 - Conditions: Mood Modulation; Modulation of Cognition
Interventions: Dietary Supplement: Hops Extract; Other: Placebo (silica)
Sponsors: Northumbria University; The New Zealand Institute for Plant and Food Research
Recruiting - verified August 2011 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Fluticasone Propionate; Drug: Placebo for Fluticasone Propionate
Sponsor: Pfizer
Recruiting - verified January 2012 - Condition: Healthy Volunteers
Interventions: Dietary Supplement: Brocco-sprout homogenate; Dietary Supplement: Alfalfa sprout homogenate
Sponsor: Imperial College London
Recruiting - verified May 2011 - Conditions: Alzheimer's Disease; Safety; Tolerability; Blood Concentration; Healthy Volunteers
Interventions: Drug: AZD3839; Drug: AZD3839 Placebo
Sponsor: AstraZeneca
Recruiting - verified June 2011 - Condition: Healthy Volunteers
Intervention: Other: cross-linking of an emulsion drink
Sponsors: Institute of Food Research; Norfolk and Norwich University Hospitals NHS Foundation Trust
Recruiting - verified April 2011 - Condition: Chronic Obstructive Pulmonary Disease
Intervention: Drug: PUR118
Sponsors: Pulmatrix Inc.; Quotient Bioresearch
Recruiting - verified November 2011 - Conditions: Acute Respiratory Distress Syndrome (ARDS); Acute Lung Injury (ALI)
Interventions: Drug: GSK1995057 single dose; Drug: GSK1995057 repeat dose
Sponsor: GlaxoSmithKline
Recruiting - verified November 2011 - Condition: Healthy Subjects
Intervention: Drug: LEO 32731
Sponsor: LEO Pharma
Recruiting - verified March 2011 - Condition: Healthy
Interventions: Drug: ATX-101; Drug: ATX-101; Drug: Placebo
Sponsors: Kythera Biopharmaceuticals; Intendis GmbH
Recruiting - verified March 2011 - Condition: Healthy
Interventions: Drug: ATX-101; Drug: ATX-101; Drug: Placebo
Sponsors: Kythera Biopharmaceuticals; Intendis GmbH
Recruiting - verified March 2011 - Condition: Hepatitis C Infection
Interventions: Biological: MVA-NSmut; Biological: AdCh3NSmut; MVA-NSmut; Biological: AdCh3NSmut; MVA-NSmut; Biological: AdCh3NSmut ; MVA-NSmut; Biological: AdCh3NSmut; MVA-NSmut
Sponsors: Okairos; University of Oxford; Oxford University Hospitals NHS Trust; University Hospital Birmingham
Recruiting - verified October 2011 - Conditions: Scientific Terminology Rheumatoid Arthritis, Healthy Female Volunteers, Pharmacokinetics, Oral Contraceptive, Drug-drug Interaction; Laymen Terminology Level of Oral Contraceptive in Blood, Oral Contraceptive, Rheumatoid Arthritis, Drug -Drug Interaction
Interventions: Drug: fostamatinib; Drug: Microgynon® 30 (Oral contraceptive); Drug: Placebo
Sponsor: AstraZeneca
Recruiting - verified March 2011 - Condition: Tuberculosis
Interventions: Biological: C-Tb; Biological: 2 TU Tuberculin PPD RT 23 SSI
Sponsor: Statens Serum Institut
Recruiting - verified November 2010 - Conditions: Haemophilia A; Haemophilia B; Healthy
Interventions: Drug: NNC 0172-0000-2021; Drug: NNC 0172-0000-2021; Drug: placebo
Sponsor: Novo Nordisk
Recruiting - verified October 2011 - Conditions: Asthma; Health
Intervention: Other: 001
Sponsor: Centocor, Inc.
Recruiting - verified December 2011 - Conditions: Vascular Disease; Heart Disease
Interventions: Drug: NO clamp; Drug: Saline; Drug: Fluconazole; Drug: Aspirin; Drug: Combined
Sponsors: University of Edinburgh; NHS Lothian
Recruiting - verified August 2011 - Condition: Hypertension
Interventions: Drug: Azilsartan medoxomil (TAK-491); Drug: Azilsartan medoxomil (TAK-491); Drug: Azilsartan medoxomil (TAK-491); Drug: Azilsartan medoxomil (TAK-491)
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2011 - Conditions: Major Depressive Disorder; Healthy Volunteers
Intervention: Drug: Duloxetine
Sponsor: Eli Lilly and Company
Recruiting - verified September 2011 - Condition: Bowel Disease, Inflammatory
Intervention: Drug: GSK1070806
Sponsor: GlaxoSmithKline
Recruiting - verified June 2011 - Condition: Influenza
Interventions: Biological: MVA-NP+M1; Biological: MVA-NP+M1; Biological: MVA-NP+M1
Sponsors: University of Oxford; Wellcome Trust
Recruiting - verified June 2011 - Conditions: Health Status Unknown; Lung Cancer
Interventions: Genetic: DNA methylation analysis; Genetic: DNA stability analysis; Genetic: gene expression analysis; Other: epidemiologic study; Other: study of socioeconomic and demographic variables; Procedure: biopsy; Procedure: evaluation of cancer risk factors; Procedure: study of high risk factors
Sponsor: University of Liverpool Cancer Research Centre
Recruiting - verified November 2007
 |
Join Clinical Trials for Healthy Volunteers in the United Kingdom |
